Male and Female Pattern Hair Loss: Science-Backed Treatments for Androgenetic Alopecia

Androgenetic alopecia — commonly called male or female pattern hair loss — accounts for the majority of hair thinning seen in both sexes, and it behaves the same way in principle wherever it occurs: hair follicles that are genetically sensitive to androgens gradually shrink, producing finer, shorter hairs with each growth cycle until some stop producing visible hair altogether. What differs between men and women is less the mechanism than the pattern it takes and, often, how early it's correctly identified.

One mechanism, two different patterns

In men, androgenetic alopecia typically follows a recession at the temples and thinning at the crown, progressing along a well-documented sequence that clinicians still describe using the Hamilton-Norwood scale. In women, the pattern is usually diffuse thinning across the crown and a widening centre part, with the frontal hairline often preserved — a distribution first systematically classified by Ludwig nearly five decades ago and still the reference point used today. This difference in distribution is why the same underlying hormonal sensitivity can look, at first glance, like two entirely different conditions.

Recognising which pattern is present matters clinically, not just descriptively — it shapes which treatments are appropriate, how quickly progression is likely, and what a realistic long-term plan looks like.

Why it's a progressive condition, not an event

Androgenetic alopecia does not announce itself with a single dramatic episode. It's a slow miniaturisation of the follicle over years, which is exactly why the early signs most people miss — a widening part, finer regrowth, more visible scalp under bright light — tend to matter more than a single count of hairs on a pillow. By the time thinning is obvious in a photograph, the underlying process has usually been active for a considerable period already.

What has genuine evidence behind it

The treatment landscape for androgenetic alopecia is crowded, but the number of interventions with consistent, high-quality trial evidence behind them is relatively small.

• Topical minoxidil (2% or 5%) — the only over-the-counter treatment with regulatory approval for both men and women, working by prolonging the growth phase of follicles that are still active
• Oral finasteride, and to a lesser extent dutasteride — used predominantly in men, reducing the conversion of testosterone to the more follicle-damaging DHT; used more selectively in women given contraindications in pregnancy
• Low-level laser therapy — supported by network meta-analyses as an effective option in both sexes, though it requires consistent long-term use to maintain its effect
• Platelet-rich plasma — most useful as an adjunct to the above rather than a stand-alone treatment, with evidence still less mature than for minoxidil or finasteride

A hormonally driven, genetically determined condition needs a treatment matched to that biology — not a routine borrowed from a product shelf.

Why scalp health still matters even with a hormonal driver

None of the treatments above work in isolation from the environment the follicle sits in. Circulation, inflammation and buildup at the scalp level can either support or undermine a follicle's response to hormonal treatment, which is why scalp assessment remains the foundation of a considered treatment plan rather than an afterthought once medication has been started.

What androgenetic alopecia is not

It's worth being precise about what this condition isn't, because the distinction changes the treatment entirely. Androgenetic alopecia is patterned and progressive; it is a different process from the diffuse, whole-scalp shedding of telogen effluvium — the kind triggered by childbirth or by a physiological shock like rapid weight loss or acute stress. The two can coexist, but treating one as though it were the other typically means both being managed less effectively.

This distinction also explains why a generic hair-thickening treatment sold at a salon rarely resolves a hormonally driven pattern — the difference between what a hair spa offers and what a medical assessment addresses is, in large part, the difference between managing the surface and managing the actual driver underneath it.